Menopur

Menotrophin, the active ingredient in Menopur, is a gonadotropin presented as an injectable solution for intramuscular and subcutaneous use. It supplies both follicle‑stimulating hormone (FSH) and luteinising hormone (LH) activity to promote ovarian follicular development and ovulation, and is indicated for infertility due to anovulation, for controlled ovarian hyperstimulation in assisted reproductive technologies, and for ovulation induction in women with hypogonadotropic hypogonadism.

GNH USA supplies Menopur as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Menotrophin is used in reproductive medicine to modulate gonadotropin pathways and support ovulation. - Infertility due to anovulation: stimulates follicular growth to enable ovulation. - Controlled ovarian hyperstimulation for IVF/ICSI: enhances multiple follicle development to increase oocyte yield. - Hypogonadotropic hypogonadism: provides exogenous FSH/LH to induce ovulation in women with deficient gonadotropin secretion.

Menopur may cause a range of adverse reactions, which are generally classified by frequency and severity.

Common Side Effects: - Injection site pain: mild discomfort or erythema at the injection site. - Abdominal bloating: transient abdominal distension. - Headache: mild to moderate headache. - Nausea: occasional nausea.

Serious or Rare Side Effects: - Ovarian hyperstimulation syndrome (OHSS): potentially severe fluid shift and thrombosis risk. - Multiple pregnancy: increased chance of twins or higher‑order gestations. - Allergic reaction: rash, urticaria, or anaphylaxis.

When prescribing Menopur, clinicians should observe several precautionary measures to minimise risk. - Assess baseline ovarian reserve: evaluate antral follicle count and hormone levels before initiating therapy. - Monitor estradiol levels: frequent serum estradiol measurements to detect excessive response. - Ultrasound surveillance: perform serial transvaginal ultrasounds to track follicle development and identify OHSS early. - Adjust dose in renal impairment: consider reduced dosing in patients with severe renal dysfunction. - Contraindications: avoid use in active ovarian cysts, uncontrolled thyroid disease, or estrogen‑dependent tumors. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Menotrophin can interact with other agents that influence ovarian response or hormone metabolism.

Major Interactions (Avoid): - GnRH agonists/antagonists: concurrent use may amplify ovarian stimulation and increase OHSS risk. - Aromatase inhibitors: may blunt estrogen rise, reducing efficacy of Menotrophin. - Anticoagulants: heightened risk of thrombosis if OHSS develops.

Moderate Interactions (Monitor Closely): - Thyroid hormone therapy: altered thyroid status can affect ovarian response; monitor thyroid function. - Corticosteroids: may modify steroidogenesis pathways; observe for hormonal fluctuations. - Diuretics: may mask early signs of fluid shift in OHSS; monitor fluid balance.